ClinicalTrials.gg
CompletedNCT02508207Updated Jul 19, 2021Results posted

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

A Phase 2 interventional study of Tezacaftor/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
40th of 43
34 · median 100
Started
2016
with 5 others
Phase 2
8 of 43
none open now
Registered
7th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 40th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 7th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

To evaluate the clinical mechanisms of action in lung and extrapulmonary systems of VX-661 (tezacaftor; TEZ) in combination with ivacaftor (IVA) (TEZ/IVA) in participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants, homozygous for the F508del CFTR mutation
  • Confirmed diagnosis of CF by sweat chloride testing
  • (FEV1) ≥40% and ≤90% of predicted normal for age, sex, and height at Screening Visit
  • Stable CF disease as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1
  • History or evidence of findings on ophthalmologic examination during the Screening Period.
  • History of solid organ or hematological transplantation
  • Pregnant or nursing females
  • Participants who have had radiation exposure within 1 year before the first mucociliary clearance (MCC) procedure that would cause them to exceed federal regulations by participating in this study
  • In the opinion of the investigator, unable to adequately perform inhalation maneuvers during the MCC procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.

    Drug: Tezacaftor/Ivacaftor matching placebo · Drug: Ivacaftor matching placebo

  • Experimental
    TEZ/IVA

    Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.

    Drug: Tezacaftor/Ivacaftor · Drug: Ivacaftor

Interventions

  • DrugTezacaftor/Ivacaftor

    Drug pages: Tezacaftor · Ivacaftor

    Tezacaftor/Ivacaftor FDC

  • DrugTezacaftor/Ivacaftor matching placebo
  • DrugIvacaftor matching placebo
06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28

    MCC was assessed using an imaging technique that enables the tracking of mucus within the airways. MCC was expressed as the percentage of whole-lung clearance through 60 minutes at Baseline and Day 28.

    Time frame: Baseline, Day 28

Secondary outcomes

  1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28

    Percent predicted FEV1 is the ratio of FEV1 to the predicted FEV1, expressed as a percentage. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 28

  2. Absolute Change From Baseline in Small-bowel Area Under the Curve (AUC) Over 1-minute Mean pH Increments at Day 29

    Absolute change from Baseline in small bowel AUC over 1-minute mean pH increments through 30 minutes at Day 29 was assessed.

    Time frame: Baseline, Day 29

  3. Absolute Change From Baseline in Sweat Chloride at Day 29

    Time frame: Baseline, Day 29

  4. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to Day 57

07

Results

Posted Jul 27, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboTEZ/IVA
Started727
Completed727
Not completed00

Outcome measures

PrimaryAbsolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28

MCC was assessed using an imaging technique that enables the tracking of mucus within the airways. MCC was expressed as the percentage of whole-lung clearance through 60 minutes at Baseline and Day 28.

Time frame:
Baseline, Day 28
Reported as:
Mean · percentage of whole-lung clearance
Absolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28
percentage of whole-lung clearancePlaceboTEZ/IVA
Absolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28-0.5 ± 11.2-0.9 ± 12.1
Statistical analysis
  • TEZ/IVA · t-test, 2 sided · p = 0.7151 (p-value for within TEZ/IVA group was analyzed using a 2-sided, paired, t-test at a 5% level of significance.)
SecondaryAbsolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28

Percent predicted FEV1 is the ratio of FEV1 to the predicted FEV1, expressed as a percentage. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 28
Reported as:
Mean · percentage of predicted FEV1
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28
percentage of predicted FEV1PlaceboTEZ/IVA
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28-0.4 ± 5.92.4 ± 3.1
Statistical analysis
  • TEZ/IVA · t-test, 2 sided · p = 0.0004 (p-value for within TEZ/IVA group was analyzed using a 2-sided, paired, t-test at a 5% level of significance.)
SecondaryAbsolute Change From Baseline in Small-bowel Area Under the Curve (AUC) Over 1-minute Mean pH Increments at Day 29

Absolute change from Baseline in small bowel AUC over 1-minute mean pH increments through 30 minutes at Day 29 was assessed.

Time frame:
Baseline, Day 29
Reported as:
Mean · pH minutes
Absolute Change From Baseline in Small-bowel Area Under the Curve (AUC) Over 1-minute Mean pH Increments at Day 29
pH minutesPlaceboTEZ/IVA
Absolute Change From Baseline in Small-bowel Area Under the Curve (AUC) Over 1-minute Mean pH Increments at Day 290.3 ± 0.5-0.2 ± 0.8
Statistical analysis
  • TEZ/IVA · t-test, 2 sided · p = 0.3345p-value for within TEZ/IVA group was analyzed using a 2-sided, paired, t-test at a 5% level of significance.
SecondaryAbsolute Change From Baseline in Sweat Chloride at Day 29
Time frame:
Baseline, Day 29
Reported as:
Mean · millimoles per liter
Absolute Change From Baseline in Sweat Chloride at Day 29
millimoles per literPlaceboTEZ/IVA
Absolute Change From Baseline in Sweat Chloride at Day 29-0.2 ± 6.0-8.4 ± 9.2
Statistical analysis
  • TEZ/IVA · t-test, 2 sided · p = 0.0002 (p-value for within TEZ/IVA group was analyzed using a 2-sided, paired, t-test at a 5% level of significance.)
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboTEZ/IVA
Participants with SAEs00
Participants with AEs224

Adverse events

Collected over Baseline up to Day 57: 29 days of dosing + 28 days of safety follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/7 (0%)0/7 (0%)2/7 (28.6%)
TEZ/IVA0/27 (0%)0/27 (0%)18/27 (66.7%)
Most frequent other events
Most frequent other events
EventPlaceboTEZ/IVA
CoughRespiratory, thoracic and mediastinal disorders0/78/27
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/77/27
Renal impairmentRenal and urinary disorders1/70/27
ArthralgiaMusculoskeletal and connective tissue disorders1/70/27
HaemoptysisRespiratory, thoracic and mediastinal disorders0/73/27
NauseaGastrointestinal disorders0/73/27
Sputum increasedRespiratory, thoracic and mediastinal disorders0/72/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTEZ/IVATotal
Mean38 ± 11.832.1 ± 8.633.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTEZ/IVATotal
Female41519
Male31215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTEZ/IVATotal
Hispanic or Latino000
Not Hispanic or Latino72734
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTEZ/IVATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White72734
More than one race000
Unknown or Not Reported000
Mucociliary Clearance (MCC): Percentage of Whole-lung Clearance
Mucociliary Clearance (MCC): Percentage of Whole-lung Clearance(percentage of whole-lung clearance)PlaceboTEZ/IVATotal
Mean15.3 ± 15.118.4 ± 11.317.8 ± 12.0
Small-bowel Area Under the Curve (AUC) Over 1-minute Mean pH Increments
Small-bowel Area Under the Curve (AUC) Over 1-minute Mean pH Increments(pH minutes)PlaceboTEZ/IVATotal
Mean5.8 ± 0.45.7 ± 0.65.8 ± 0.6
08

Study locations

7 sites
  • Birmingham, Alabama, United States
  • Indianapolis, Indiana, United States
  • Baltimore, Maryland, United States
  • Chapel Hill, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Toledo, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2015
First posted
Jul 24, 2015
Start
Feb 2016
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Results first posted
Jul 27, 2018
Last update
Jul 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02508207
Responsible party
Sponsor
First posted
Jul 24, 2015
Start date
Feb 2016
Primary completion
Jun 2017
Completion
Jun 2017
Results posted
Jul 27, 2018
Last update
Jul 19, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion